These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11940476)

  • 1. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
    Ribatti D; Vacca A
    Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide.
    Waldman AR
    Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thalidomide--new prospective therapy in oncology].
    Pałgan K; Pałgan I
    Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide--a revival story.
    Raje N; Anderson K
    N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
    [No Abstract]   [Full Text] [Related]  

  • 6. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

  • 7. [New observations support the significance of angiogenesis in myeloma].
    Lundberg LG; Lerner R; Palmblad J
    Lakartidningen; 2001 Nov; 98(45):4985-90. PubMed ID: 11816901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells.
    Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T
    Int J Oncol; 2003 Jan; 22(1):165-73. PubMed ID: 12469200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide: from teratogen to anti-angiogenic.
    Grover JK; Vats K
    Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
    Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 16. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
    Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
    Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
    Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
    J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.